Integrating Addiction Treatment and Medical Care in a Commercial Health Plan

将成瘾治疗和医疗保健纳入商业健康计划

基本信息

  • 批准号:
    8675816
  • 负责人:
  • 金额:
    $ 64.84万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-07-01 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Twelve addiction treatment centers and Aetna Behavioral Health collaborate using the Advancing Recovery systems change model to increase the proportion of patients with medication-assisted treatment for alcohol or opioid dependence. The addiction treatment centers participate in a 22-month test of the system change strategy to enhance access to medication for patients dependent on opioids or alcohol. The proposal has three specific aims: 1) facilitate adoption of medications, 2) assess impacts on healthcare utilization and expenditures, and 3) conduct qualitative interviews and document implementation barriers and change strategies. Analyses of Aetna's databases track use of health and behavioral health services to assess medication impacts on the utilization and cost of care. Specific Aim 1: Use the Advancing Recovery model of system change to accelerate the implementation of medication-assisted treatment and integration with medical care; assign 12 addiction treatment centers to Advancing Recovery and compare to 12 matched comparison sites. 7 H1A: The proportion of opioid and alcohol admissions with prescriptions for addiction medications is greater in centers using the Advancing Recovery system change model. 7 H1B: Advancing Recovery sites form linkages with more prescribers and have more physicians writing prescriptions for patients. Specific Aim 2: Assess impacts on the utilization of and expenditures for inpatient, emergency and residential care using Aetna's utilization and expenditures data. 7 H2A: Utilization of and expenditures for inpatient medical care, emergency services, and residential addiction treatment will be lower among patients treated in sites participating in Advancing Recovery. 7 H2B: Utilization of and expenditures for inpatient medical care, emergency services, and residential addiction treatment will be lower among patients treated with addiction medications. 7 H2C: Utilization of and expenditures for inpatient medical care, emergency services, and residential addiction treatment will be lower among patients with more consecutive months of medication prescriptions. Specific Aim 3: Conduct qualitative interviews to document implementation barriers and effective implementation strategies for medication assisted treatment. 7 H3A: Provider training and attitudes are more problematic barriers to adoption than payment and reimbursement issues. 7 H3B: Centers with no experience with buprenorphine will be more likely to use extended release naltrexone for treatment of opioid dependence.
描述(由申请人提供):十二家成瘾治疗中心和 Aetna 行为健康部门合作,使用推进康复系统变革模型来增加接受药物辅助治疗的酒精或阿片类药物依赖患者的比例。成瘾治疗中心参与了为期 22 个月的系统变革策略测试,以提高阿片类药物或酒精依赖患者获得药物的机会。该提案具有三个具体目标:1)促进药物的采用,2)评估对医疗保健利用和支出的影响,3)进行定性访谈并记录实施障碍和变革策略。对 Aetna 数据库的分析跟踪健康和行为健康服务的使用情况,以评估药物对护理利用率和成本的影响。具体目标1:利用制度变革的推进康复模式,加快药物辅助治疗和医疗融合的实施;将 12 个成瘾治疗中心分配给 Advancing Recovery,并与 12 个匹配的比较站点进行比较。 7 H1A:在使用推进康复系统变革模型的中心,服用成瘾药物处方的阿片类药物和酒精入院比例较高。 7 H1B:推进康复网站与更多处方者建立联系,并让更多医生为患者开处方。具体目标 2:使用 Aetna 的利用和支出数据评估住院、急诊和住院护理的利用和支出的影响。 7 H2A:在参与“推进康复”的地点接受治疗的患者中,住院医疗护理、紧急服务和住院成瘾治疗的利用率和支出将会较低。 7 H2B:接受成瘾药物治疗的患者对住院医疗护理、紧急服务和住院成瘾治疗的利用和支出将会较低。 7 H2C:连续开药月数越多的患者,住院医疗、急诊服务和住院成瘾治疗的利用率和支出将会更低。具体目标 3:进行定性访谈,记录药物辅助治疗的实施障碍和有效实施策略。 7 H3A:与付款和报销问题相比,提供者培训和态度是更严重的采用障碍。 7 H3B:没有丁丙诺啡经验的中心更有可能使用缓释纳曲酮来治疗阿片类药物依赖。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DENNIS MCCARTY其他文献

DENNIS MCCARTY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DENNIS MCCARTY', 18)}}的其他基金

Oregon's Coordinated Care Organizations Integrate Care for Drug Use Disorders
俄勒冈州的协调护理组织整合吸毒障碍护理
  • 批准号:
    8535305
  • 财政年份:
    2013
  • 资助金额:
    $ 64.84万
  • 项目类别:
Oregon's Coordinated Care Organizations Integrate Care for Drug Use Disorders
俄勒冈州的协调护理组织整合吸毒障碍护理
  • 批准号:
    8823045
  • 财政年份:
    2013
  • 资助金额:
    $ 64.84万
  • 项目类别:
Oregon's Coordinated Care Organizations Integrate Care for Drug Use Disorders
俄勒冈州的协调护理组织整合了吸毒障碍护理
  • 批准号:
    8836995
  • 财政年份:
    2013
  • 资助金额:
    $ 64.84万
  • 项目类别:
Oregon's Coordinated Care Organizations Integrate Care for Drug Use Disorders
俄勒冈州的协调护理组织整合吸毒障碍护理
  • 批准号:
    8776185
  • 财政年份:
    2013
  • 资助金额:
    $ 64.84万
  • 项目类别:
Integrating Addiction Treatment and Medical Care in a Commercial Health Plan
将成瘾治疗和医疗保健纳入商业健康计划
  • 批准号:
    8479329
  • 财政年份:
    2011
  • 资助金额:
    $ 64.84万
  • 项目类别:
Integrating Addiction Treatment and Medical Care in a Commercial Health Plan
将成瘾治疗和医疗保健纳入商业健康计划
  • 批准号:
    8187812
  • 财政年份:
    2011
  • 资助金额:
    $ 64.84万
  • 项目类别:
Integrating Addiction Treatment and Medical Care in a Commercial Health Plan
将成瘾治疗和医疗保健纳入商业健康计划
  • 批准号:
    8274664
  • 财政年份:
    2011
  • 资助金额:
    $ 64.84万
  • 项目类别:
Education Core
教育核心
  • 批准号:
    8882367
  • 财政年份:
    2006
  • 资助金额:
    $ 64.84万
  • 项目类别:
Education Core
教育核心
  • 批准号:
    8693986
  • 财政年份:
    2006
  • 资助金额:
    $ 64.84万
  • 项目类别:
Education Core
教育核心
  • 批准号:
    9115105
  • 财政年份:
    2006
  • 资助金额:
    $ 64.84万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 64.84万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.84万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 64.84万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.84万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 64.84万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 64.84万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.84万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 64.84万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 64.84万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.84万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了